CMB International Securities analyst Jill Wu maintained a Buy rating on Wuxi Biologics (Cayman) today and set a price target of HK$39.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jill Wu has given his Buy rating due to a combination of factors that underscore WuXi Biologics’ strong growth trajectory and earnings visibility. The company delivered double‑digit revenue and adjusted profit expansion in 2025, outpacing her forecasts, while its rapidly growing order backlog and robust 2026 guidance signal sustained demand despite macro and FX uncertainties.
She also highlights structurally attractive drivers such as accelerating early‑stage R&D projects, surging contributions from bispecific/multispecific antibody and XDC platforms, and the recovery of Phase III and commercial manufacturing activities. Together with planned capacity expansion, rising utilization at overseas sites, high‑margin milestone income, and ongoing margin uplift from the WuXi Bio Business System, these factors support her higher DCF‑derived target price and reinforce the Buy recommendation.